The serum concentration of Enalapril can be increased when it is combined with Palbociclib. Raltegravir may increase the myopathic rhabdomyolysis activities of Zidovudine. The risk or severity of adverse effects can be increased when Tinoridine is combined with Flurandrenolide. The risk or severity of adverse effects can be increased when Heparin is combined with Collagenase clostridium histolyticum. Salmeterol may increase the QTc-prolonging activities of Azithromycin. Levofloxacin may increase the QTc-prolonging activities of Paliperidone. The metabolism of Halothane can be decreased when combined with Trimethoprim. The serum concentration of Saxagliptin can be increased when it is combined with Atazanavir. Ardeparin may increase the hyperkalemic activities of Candesartan. The serum concentration of Fluticasone furoate can be increased when it is combined with Diethylstilbestrol. Fluticasone propionate may increase the hypokalemic activities of Cyclopenthiazide. The therapeutic efficacy of Metformin can be decreased when used in combination with Niacin. The serum concentration of Antipyrine can be decreased when it is combined with Peginterferon alfa-2b. The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levomethadyl Acetate. The serum concentration of Amodiaquine can be increased when it is combined with Metronidazole. Diflorasone may increase the hypokalemic activities of Bendroflumethiazide. Semapimod may decrease the antihypertensive activities of Bisoprolol. The serum concentration of Clonidine can be decreased when it is combined with Tocilizumab. The risk or severity of adverse effects can be increased when Amiloride is combined with Irbesartan. The risk or severity of adverse effects can be increased when Metolazone is combined with Oleandrin. The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Hydroflumethiazide. The metabolism of Ethylmorphine can be decreased when combined with Lumefantrine. Pentoxifylline may increase the anticoagulant activities of Heparin. Salbutamol may increase the QTc-prolonging activities of Sotalol. Indacaterol may increase the hypokalemic activities of Mometasone. Atazanavir may increase the QTc-prolonging activities of Levofloxacin. The serum concentration of Eliglustat can be increased when it is combined with Bupropion. The risk or severity of adverse effects can be increased when Benzocaine is combined with Tandospirone. The metabolism of Dextroamphetamine can be decreased when combined with Betaxolol. Trimethoprim may increase the QTc-prolonging activities of Propafenone. The serum concentration of Pravastatin can be increased when it is combined with Hydrocortisone. Nitroaspirin may decrease the antihypertensive activities of Fosinopril. The metabolism of Methyltestosterone can be decreased when combined with Indinavir. Paramethasone may increase the fluid retaining activities of Nandrolone. The risk or severity of adverse effects can be increased when Candesartan is combined with Carbaspirin calcium. Alfuzosin may increase the hypotensive activities of Candesartan. The therapeutic efficacy of Iobenguane can be decreased when used in combination with Chlorphentermine. The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ranitidine. The therapeutic efficacy of Conjugated estrogens can be decreased when used in combination with Methohexital. The risk or severity of adverse effects can be increased when Streptokinase is combined with Dexmedetomidine. The risk or severity of adverse effects can be increased when Benzocaine is combined with Methylecgonine. Apocynin may decrease the excretion rate of Neomycin which could result in a higher serum level. The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Lopinavir. The metabolism of Manidipine can be increased when combined with Hexobarbital. The serum concentration of Brompheniramine can be decreased when it is combined with Bosentan. The metabolism of Mephenytoin can be decreased when combined with Midostaurin. The risk or severity of adverse effects can be increased when Bromazepam is combined with Dextropropoxyphene. The metabolism of Flecainide can be decreased when combined with Terbinafine. The serum concentration of Trichlormethiazide can be increased when it is combined with Orphenadrine. The serum concentration of Elvitegravir can be increased when it is combined with Darunavir. The risk or severity of adverse effects can be increased when Bufexamac is combined with Estrone sulfate. The risk or severity of adverse effects can be increased when Methocarbamol is combined with Levetiracetam. Esmolol may increase the hypoglycemic activities of Tolbutamide. The metabolism of Ketobemidone can be decreased when combined with Pyrimethamine. The risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocortolone. The metabolism of Glimepiride can be decreased when combined with Omeprazole. Methylene blue may increase the hypotensive activities of Hydrochlorothiazide. The risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluprednidene. Methyclothiazide may increase the hypercalcemic activities of Dihydrotachysterol. The serum concentration of Nimodipine can be increased when it is combined with Fusidic Acid. The risk or severity of adverse effects can be increased when Amisulpride is combined with Brompheniramine. The metabolism of Tamsulosin can be decreased when combined with Ropinirole. The serum concentration of the active metabolites of Cortisone acetate can be reduced when Cortisone acetate is used in combination with Tesamorelin resulting in a loss in efficacy. The risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrabenazine. The metabolism of Phenobarbital can be increased when combined with Secobarbital. The serum concentration of Banoxantrone can be increased when it is combined with Fusidic Acid. The serum concentration of Cilostazol can be increased when it is combined with Ritonavir. The serum concentration of Tixocortol can be decreased when it is combined with St. John's Wort. Pivhydrazine may increase the hypoglycemic activities of Sulfadiazine. The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone. The serum concentration of Atorvastatin can be increased when it is combined with Ubenimex. The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinonide. Tiotropium may increase the anticholinergic activities of Sulpiride. The serum concentration of Chloroquine can be decreased when it is combined with Tromethamine. The therapeutic efficacy of Tiotropium can be decreased when used in combination with Physostigmine. The serum concentration of Hydrocodone can be increased when it is combined with Erythromycin. The risk or severity of adverse effects can be increased when Diclofenamide is combined with Empagliflozin. The risk or severity of adverse effects can be increased when Metergoline is combined with Dimethyl sulfoxide. Lipoic Acid may increase the hypoglycemic activities of Glimepiride. The metabolism of Phenacetin can be decreased when combined with Gemfibrozil. Mirabegron may increase the QTc-prolonging activities of Artemether. Amitriptyline may increase the QTc-prolonging activities of Quinidine. The serum concentration of Drospirenone can be increased when it is combined with Ceritinib. The risk or severity of adverse effects can be increased when Rescinnamine is combined with Etofenamate. The serum concentration of Protriptyline can be increased when it is combined with Simeprevir. The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Chlorphenamine. The metabolism of Amiodarone can be increased when combined with Pentobarbital. The serum concentration of Simvastatin can be increased when it is combined with Tadalafil. The metabolism of Alogliptin can be decreased when combined with Isoniazid. The metabolism of Buprenorphine can be decreased when combined with Erythromycin. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carisoprodol. The risk or severity of adverse effects can be increased when Oxycodone is combined with Brompheniramine. Nitrous oxide may increase the arrhythmogenic activities of Norepinephrine. The risk or severity of adverse effects can be increased when Ketanserin is combined with Carbaspirin calcium. The therapeutic efficacy of Nateglinide can be decreased when used in combination with Quinethazone. Nimesulide may decrease the antihypertensive activities of Metoprolol. Diclofenac may increase the anticoagulant activities of Acenocoumarol. The serum concentration of Tolvaptan can be increased when it is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Rimexolone is combined with Mefloquine. The metabolism of Timolol can be decreased when combined with Ritonavir. The therapeutic efficacy of Dydrogesterone can be decreased when used in combination with Ulipristal. The risk or severity of adverse effects can be increased when Atenolol is combined with Riociguat. Hexobarbital may increase the hypotensive activities of Iloprost. The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Hydroxyprogesterone caproate. The risk or severity of adverse effects can be increased when Methaqualone is combined with Citalopram. The risk or severity of adverse effects can be increased when Clobetasone is combined with Neostigmine. The risk or severity of adverse effects can be increased when Milrinone is combined with Acetylsalicylic acid. The serum concentration of Tixocortol can be decreased when it is combined with Pentobarbital. Zimelidine may increase the hyponatremic activities of Cyclopenthiazide. Insulin Pork may increase the hypoglycemic activities of Chlorpropamide. The serum concentration of Quetiapine can be increased when it is combined with Ketoconazole. The metabolism of Mexiletine can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Azelastine is combined with Flunisolide. Amobarbital may increase the hypotensive activities of Propranolol. The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Bumetanide. The risk or severity of adverse effects can be increased when Lorazepam is combined with Trichloroethylene. The metabolism of Cevimeline can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Chloroquine is combined with Desoximetasone. Amphetamine may increase the analgesic activities of Opium. Ritobegron may increase the analgesic activities of Ethylmorphine. Diclofenac may increase the neuroexcitatory activities of Gemifloxacin. The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estrone. The risk or severity of adverse effects can be increased when Drotebanol is combined with Opium. The metabolism of Histamine can be decreased when combined with Dihydroergotamine. The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluocortolone. Nadolol may increase the orthostatic hypotensive activities of Bucindolol. The serum concentration of Chlorothiazide can be increased when it is combined with Trihexyphenidyl. The metabolism of Vortioxetine can be decreased when combined with Irbesartan. The risk or severity of adverse effects can be increased when Triamcinolone is combined with Flumequine. The risk or severity of adverse effects can be increased when Desflurane is combined with Cilazapril.